ArticlePloS one2026
Gene expression and metadata based identification of key genes for lung cancer, COPD, and IPF using machine learning and statistical models.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer (LC) is one of the most prevalent and deadly cancers globally, presenting a major public health challenge. Patients with chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) are at a significantly higher risk of developing lung cancer. Despite developments in research, the primary molecular pathways of many disorders remain poorly understood. The current study aimed to identify potential therapeutic genes for lung cancer (LC), chronic obstructive pulmonary disease (COPD), and idiopathic pulmonary fibrosis (IPF) through machine learning (ML) and bioinformatics methodologies. The differentially expressed genes (DEGs) were identified across three datasets utilising DESeq2 and limma, and the common genes among the DEGs from these datasets were subsequently selected. The protein-protein interaction (PPI) networks were generated utilising STRING, and major hub genes were discerned via topological analysis. The Key hub genes, such as ETS1, MSH2, RORA, and PMAIP1, were detected. The pathways named KEGG and cancer pathway studies were conducted to evaluate their contributions to disease processes. The research included network-based methodologies, including transcription factors, GO keywords, gene-miRNA relationships, and survival data analyses, to further narrow the list of differential genes linked to LC, COPD, and IPF. The metadata for hub genes was aggregated from prior studies to integrate earlier discoveries. In the end, four key candidate genes (ETS1, MSH2, RORA, and PMAIP1) were found by intersecting the common differentially expressed genes, hub genes, major module genes, and meta-hub genes. The outcomes present a solid framework for subsequent research and therapy strategies for LC, COPD, and IPF. The potential drug compounds targeting the identified key genes are proposed, offering new avenues for the development of treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.